BMO Capital Downgrades Nightstar Therapeutics (NITE) to Market Perform Following Acquisition
Tweet
Share
E-mailGet Alerts NITE Hot Sheet
Price: $39.42 --0%
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
BMO Capital analyst Matthew Luchini downgraded Nightstar Therapeutics (NASDAQ: NITE) from Outperform to Market Perform with a price target of $25.50.
For an analyst ratings summary and ratings history on Nightstar Therapeutics click here. For more ratings news on Nightstar Therapeutics click here.
Shares of Nightstar Therapeutics closed at $25.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- BMO Capital Starts Semtech Corp. (SMTC) at Outperform
- BMO Capital Starts NVIDIA (NVDA) at Outperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
